The company has not filed an annual or quarterly report since its Q1 FY2022 10-Q, filed May 5, 2022. Its latest SEC filing is a 15-12B from Jun 13, 2022.
10-Q for Q1 FY2022, filed May 5, 2022
The sections below describe the company as of the FY2021 annual report.
Develops cancer vaccines and cell therapies using a platform that identifies tumor targets for cancer patients.
10-K for FY2021, filed Mar 18, 2022We are a biopharmaceutical company dedicated to discovering and developing novel cancer immunotherapies using our proprietary ATLASTM…View ↗
GEN-011 is an investigational next-generation solid tumor cell therapy candidate comprised of CD4+ and CD8+ neoantigen-targeted peripheral…View ↗
GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. We…View ↗
Genocea receives fees and research funding from pharmaceutical partners for ATLAS-based research and related services; it earns the service portion as it performs the work.
10-K for FY2021, filed Mar 18, 2022In December 2021, the Company entered into a collaboration and option agreement (the “Janssen Agreement”) with Janssen Biotech, Inc.…View ↗
The Company determined that its grant of a limited-use research license to Janssen and its conduct of R&D Services should be accounted for…View ↗
The Company had not provided any services under the Janssen Agreement as of December 31, 2021, and as such, the upfront fee of $1.7 million…View ↗
$1.6M
10-K for FY2021, filed Mar 19, 2022
$1.6M ↗
Pharmaceutical companies engage Genocea directly for research and development services or antigen materials.
10-K for FY2021, filed Mar 18, 2022
No. It lost $33.2M in FY2021.
10-K for FY2021, filed Mar 19, 2022
−$52.1MView ↗
10-K for FY2021, filed Mar 19, 2022
−$33.2MView ↗
10-K for FY2021, filed Mar 19, 2022
−$48.7MView ↗
10-Q for Q1 FY2022, filed May 6, 2022
−$16MView ↗
8-K, filed May 24, 2022
As described in Item 8.01 below, on May 20, 2022, the Board of Directors of Genocea Biosciences, Inc. (the "Company") voted to wind down…View ↗
Competes with Achilles Therapeutics, Adaptimmune Therapeutics, BioNTech, F. Hoffmann-La Roche, Iovance Biotherapeutics, Instil Bio, Lyell Immunopharma, Neogene Therapeutics, PACT Pharma, Ziopharm Oncology, CureVac, Genentech, Gritstone Oncology, Merck &, Moderna, Nouscom, and Vaccibody
10-K for FY2021, filed Mar 18, 2022There are several companies attempting to develop cellular therapies targeted towards neoantigens, either through transferring T cells that…View ↗
Loading...
